A Deal to Get Cheaper and Safer Drugs.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    New York Times. 8/18/2011, Vol. 160 Issue 55501, p20. 0p.
  • Additional Information
    • Subject Terms:
      GENERIC drugs; MEDICAL care costs; PHARMACEUTICAL industry; UNITED States. Food & Drug Administration
    • Subject Terms:
      UNITED States
    • Abstract:
      Federal regulators and the generic drug industry are putting the final touches on an agreement that would help speed the approval of generic drugs in this country and increase inspections at foreign plants that export generic drugs and drug ingredients to the United States. The agreement calls for generic drug manufacturers to collectively pay $299 million in annual fees (adjusted for inflation in succeeding years) under a program that would have to be approved by Congress. The fees would allow the Food and Drug Administration to hire more reviewers to speed up the processing of applications to market new generics and reduce a large current backlog. That would help lower health care costs by giving patients and doctors quicker access to inexpensive generics. [ABSTRACT FROM PUBLISHER]
    • Abstract:
      Copyright of New York Times is the property of New York Times and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)